attomarker.com
Antibody Screening | Attomarker
http://attomarker.com/services/antibody-screening
Recovery from Elective Surgery. Attomarker has a proprietary label-free multiplex technology that it uses to study protein interactions. Our results to-date in characterising antibody affinities and in identifying the glycosylation patterns in proteins that impart their function in vivo have been published. We are now offering access to this technology as a service to the life science industry to give you that competitive edge in Quality Control and Quality Assurance of your products. Comparative kinetic...
attomarker.com
Recovery from Elective Surgery | Attomarker
http://attomarker.com/products/recovery-from-elective-surgery
Recovery from Elective Surgery. Recovery from Elective Surgery. Attomarker is currently developing a Recovery Profile Array that will provide information on the response of the immune system during the recovery of a patient following elective surgery. The array is currently undergoing clinical trials. Innovation Centre, University of Exeter, Rennes Drive, EX4 4RN.
attomarker.com
Chemical Intermediates | Attomarker
http://attomarker.com/services/chemical-intermediates
Recovery from Elective Surgery. 5-Fluoro-1,3-di(2-propyn-1-yl)-2,4(1H,3H)-pyrimidinedione. Innovation Centre, University of Exeter, Rennes Drive, EX4 4RN.
attomarker.com
Twitter Feed | Attomarker
http://attomarker.com/twitter-feed
Recovery from Elective Surgery. Innovation Centre, University of Exeter, Rennes Drive, EX4 4RN.
attomarker.com
Allergy | Attomarker
http://attomarker.com/products/allergy
Recovery from Elective Surgery. Attomarker Ltd is developing an Allergy Screening Array that profiles the response of the immune system to the allergens, looking at all antibody profiles, including the conventional serum tests for IgE. The profile analysis leads to an understanding of allergy and intolerance that is unique amongst tests currently performed on the skin or in the blood. To read references related to our allergy screening techniques and applications.
attomarker.com
Attomarker Services | Attomarker
http://attomarker.com/services
Recovery from Elective Surgery. Lifetime plot for characterising the Fab-Fc regions of an antibody. Attomarker offers a competitively priced Custom Synthesis service with a focus on short lead-times, high analytical standards and confidentiality. We also have a proprietary label-free multiplex technology that it uses to study protein interactions. You can find out more about each of these services using the links below. Innovation Centre, University of Exeter, Rennes Drive, EX4 4RN.
attomarker.com
Custom Synthesis | Attomarker
http://attomarker.com/services/custom-synthesis
Recovery from Elective Surgery. Attomarker offers a Custom Synthesis service that is competitively priced, with a focus on short lead-times, high analytical standards and confidentiality. Our team of PhD chemists each have a minimum of 8 years postgraduate experience, with a success rate of 95% for custom projects. 13C NMR and other nuclei. HPLC or chiral HPLC. Pharmaceutical or Agrochemical Intermediates. SEM and TEM imaging. Heterocyclic Chemistry, High-Pressure Reductions, Aminations, Carbonylations.
attomarker.com
Product Summary | Attomarker
http://attomarker.com/products
Recovery from Elective Surgery. Attomarker has developed a novel array-format, label-free detection technology that is able to measure 100 different analytes from whole blood in 10 minutes. The technology has been developed in Prof Andrew Shaw’s Research Group. Innovation Centre, University of Exeter, Rennes Drive, EX4 4RN.
attomarker.com
About Us | Attomarker
http://attomarker.com/about-us
Recovery from Elective Surgery. Attomarker was established in December 2008 as a spin-out company from the University of Exeter, through which to exploit the IP generated from a Basic Technology Research Grant awarded to a collaboration led by Prof Andrew Shaw. Supported by a seed investment, the company has completed its proof of concept studies with a grant for R&D awarded by the South West Regional Development Agency. Dr Mark Fisher (CEO). Innovation Centre, University of Exeter, Rennes Drive, EX4 4RN.